Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Novel PKC Inhibitor Shows Promise for Amphetamine Use Disorders.

Literature DB >> 28593999

A Novel PKC Inhibitor Shows Promise for Amphetamine Use Disorders.

Amy H Newman¹.

Abstract

Entities: Chemical

Year: 2017 PMID： 28593999 PMCID： PMC5561339 DOI： 10.1038/npp.2017.116

Source DB: PubMed Journal: Neuropsychopharmacology ISSN： 0893-133X Impact factor: 7.853

× No keyword cloud information.

6 in total

1. Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors: Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal: Bioorg Med Chem Date: 2016-09-04 Impact factor: 3.641

Review 2. Tamoxifen use for the management of mania: a review of current preclinical evidence.

Authors: Fernanda Armani; Monica Levy Andersen; José Carlos Fernandes Galduróz
Journal: Psychopharmacology (Berl) Date: 2014-01-18 Impact factor: 4.530

3. Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Authors: Colleen Carpenter; Alexander G Zestos; Rachel Altshuler; Roderick J Sorenson; Bipasha Guptaroy; Hollis D Showalter; Robert T Kennedy; Emily Jutkiewicz; Margaret E Gnegy
Journal: Neuropsychopharmacology Date: 2017-05-11 Impact factor: 7.853

1 in total

Review 1. Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors: Zhongwei Liu; Raouf A Khalil
Journal: Biochem Pharmacol Date: 2018-02-13 Impact factor: 5.858

1 in total

A Novel PKC Inhibitor Shows Promise for Amphetamine Use Disorders.

1. Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Review 2. Tamoxifen use for the management of mania: a review of current preclinical evidence.

3. Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Review 4. Pharmacotherapy of amphetamine-type stimulant dependence: an update.

5. PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.

6. Inhibition of protein kinase C by tamoxifen.

Review 1. Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.